ArticleNeuro-oncology advances
Tertiary lymphoid structures in glioblastoma: Association with multiparametric MRI imaging phenotypic features and patient survival.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunology and cell biology · 2026Review
- Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLSs) correlate with improved survival in various cancers, but their prognostic significance and imaging correlations in glioblastoma (GBM) remain unclear. This study investigated the relationship between TLSs, survival outcomes, and imaging features in GBM patients. Methods: A retrospective analysis of 190 newly diagnosed GBM patients was conducted. TLSs were identified via hematoxylin-eosin staining, with maturity assessed by multiplex immunofluorescence (CD20/CD3/CD21/CD23) into mature (mTLSs) and immature (imTLSs) subgroups. Survival analysis used Kaplan-Meier method, and TLS predictive models were developed via logistic regression. Clinicopathological and VASARI imaging features were compared. Results: Of 190 cases, 85 (44.73%) were TLSs+, comprising 47 imTLSs and 38 mTLSs. Mean overall survival (OS) was 11.82 months. Significant OS differences were observed between TLSs+ (14.67 months) and TLSs- (9.51 months) groups, and between mTLSs (19.36 months) and imTLSs (10.87 months) groups (all Conclusion: TLSs exist at varying maturation stages in GBM and represent favorable prognostic biomarkers. Their presence and maturity significantly correlate with OS and specific VASARI features. Preoperative imaging prediction of TLSs may facilitate risk stratification and individualized treatment for GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.